Midatech Pharma plc logo
Midatech Pharma plc MTP

Annual report 2024
added 03-21-2026

report update icon

Midatech Pharma plc EPS Ratio 2011-2026 | MTP

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Midatech Pharma plc

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - -31 -56 -36 - - - -

All numbers in GBP currency

Indicator range from annual reports

Maximum Minimum Average
-31 -56 -41

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
Altimmune Altimmune
ALT
-1 $ 3.41 2.1 % $ 300 M usaUSA
Amgen Amgen
AMGN
14.3 $ 350.17 0.68 % $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 19.57 0.36 % $ 915 M usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-8.28 $ 217.82 -1.83 % $ 5 B danmarkDanmark
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-0.86 $ 1.4 1.82 % $ 357 M britainBritain
Aytu BioScience Aytu BioScience
AYTU
-2.16 $ 2.64 1.15 % $ 16.6 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-13.7 - -10.17 % $ 12.2 K usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
-0.21 $ 11.0 0.18 % $ 453 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
-1.77 - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.51 - 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Avenue Therapeutics Avenue Therapeutics
ATXI
-15.8 - -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
1.43 $ 1.58 3.62 % $ 185 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-2.55 $ 3.35 0.3 % $ 116 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
Cullinan Management Cullinan Management
CGEM
2.46 $ 12.83 0.71 % $ 773 M usaUSA
Atreca Atreca
BCEL
-2.52 - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Cara Therapeutics Cara Therapeutics
CARA
-2.19 - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-1.89 - - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
CorMedix CorMedix
CRMD
2.25 $ 6.29 0.64 % $ 453 K usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
-0.15 $ 4.41 -1.01 % $ 608 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-1.42 - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
-2.29 - -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
0.38 $ 2.12 1.2 % $ 198 M israelIsrael
Denali Therapeutics Denali Therapeutics
DNLI
-2.57 $ 20.92 3.69 % $ 3.44 B usaUSA
Dyadic International Dyadic International
DYAI
-0.24 $ 0.89 -5.85 % $ 25.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-0.44 $ 4.26 0.47 % $ 707 M canadaCanada
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA